Olanzapina Doc (Olanzapine)

Olanzapine, the active ingredient in Olanzapina Doc, is an atypical antipsychotic presented as a tablet for oral use. It is used to treat schizophrenia and bipolar disorder in adults, helping to control psychotic symptoms and mood swings. GNH USA supplies Olanzapina Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways, and is indicated for the following conditions: - Schizophrenia: reduces hallucinations, delusions and other psychotic symptoms. - Bipolar I disorder (manic episodes): stabilises mood and decreases manic symptoms. - Acute agitation associated with schizophrenia or bipolar disorder: provides rapid calming effect.

Olanzapine may cause a range of adverse reactions.

Common Side Effects: - Weight gain: increased appetite and body mass. - Sedation: drowsiness or fatigue. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness, especially on standing. - Increased appetite: may contribute to weight gain.

Serious or Rare Side Effects: - Hyperglycaemia/diabetes mellitus: elevated blood glucose levels. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Tardive dyskinesia: involuntary movements with long‑term use. - Agranulocytosis: severe reduction in white blood cells. - Severe orthostatic hypotension: marked blood pressure drop on standing. - Myocarditis: inflammation of the heart muscle, very rare.

Before initiating therapy, consider the following precautions: - Pregnancy: use only if potential benefit justifies the potential risk to the fetus. - Lactation: olanzapine is excreted in breast milk; weigh benefits against possible infant exposure. - Elderly patients with dementia: increased risk of mortality; avoid unless clearly indicated. - Metabolic monitoring: regularly assess weight, glucose, and lipid levels. - Discontinuation: taper dose gradually to minimise withdrawal or rebound symptoms. - Store at room temperature: keep in the original container, protect from moisture and light.

Olanzapine can interact with several medicines.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise olanzapine plasma concentrations. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - Strong anticholinergic agents: may exacerbate anticholinergic side effects.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce olanzapine effectiveness. - Other antipsychotics: increased risk of QT prolongation and cardiac effects. - Lithium: monitor for neurotoxicity when used together.